US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

ADAG

Adagene (ADAG)

Adagene Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ADAG

Fecha	Hora	Fuente	Título	Símbolo	Compañía
22/05/2024	15:45	GlobeNewswire Inc.	Adagene to Present at Investor Conferences in June	NASDAQ:ADAG	Adagene Inc
29/03/2024	08:00	GlobeNewswire Inc.	Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
07/03/2024	15:01	GlobeNewswire Inc.	Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board	NASDAQ:ADAG	Adagene Inc
01/03/2024	15:30	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:ADAG	Adagene Inc
27/02/2024	07:00	GlobeNewswire Inc.	Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	NASDAQ:ADAG	Adagene Inc
09/02/2024	05:08	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ADAG	Adagene Inc
09/02/2024	05:00	GlobeNewswire Inc.	Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stab	NASDAQ:ADAG	Adagene Inc
16/01/2024	16:01	GlobeNewswire Inc.	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	NASDAQ:ADAG	Adagene Inc
04/01/2024	04:00	GlobeNewswire Inc.	Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium	NASDAQ:ADAG	Adagene Inc
03/11/2023	11:00	GlobeNewswire Inc.	Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023	NASDAQ:ADAG	Adagene Inc
12/10/2023	07:00	GlobeNewswire Inc.	Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting	NASDAQ:ADAG	Adagene Inc
07/09/2023	05:00	GlobeNewswire Inc.	Adagene to Present at Investor and Scientific Conferences in September	NASDAQ:ADAG	Adagene Inc
31/08/2023	06:32	GlobeNewswire Inc.	Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
04/05/2023	08:01	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:ADAG	Adagene Inc
04/05/2023	08:00	GlobeNewswire Inc.	Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate	NASDAQ:ADAG	Adagene Inc
28/04/2023	06:03	Edgar (US Regulatory)	Annual and Transition Report (foreign Private Issuer) (20-f)	NASDAQ:ADAG	Adagene Inc
28/04/2023	06:00	GlobeNewswire Inc.	Adagene Announces Updates to its Board of Directors	NASDAQ:ADAG	Adagene Inc
18/04/2023	08:17	GlobeNewswire Inc.	Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors	NASDAQ:ADAG	Adagene Inc
28/03/2023	15:30	GlobeNewswire Inc.	Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update	NASDAQ:ADAG	Adagene Inc
14/03/2023	17:00	GlobeNewswire Inc.	Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April	NASDAQ:ADAG	Adagene Inc
05/03/2023	18:39	GlobeNewswire Inc.	Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board	NASDAQ:ADAG	Adagene Inc
09/02/2023	07:16	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:ADAG	Adagene Inc
09/01/2023	06:00	GlobeNewswire Inc.	Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial	NASDAQ:ADAG	Adagene Inc
05/01/2023	15:01	GlobeNewswire Inc.	Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9	NASDAQ:ADAG	Adagene Inc
16/12/2022	05:30	GlobeNewswire Inc.	Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer	NASDAQ:ADAG	Adagene Inc
21/11/2022	15:05	GlobeNewswire Inc.	Adagene Appoints Cuong Do to Board of Directors and Audit Committee	NASDAQ:ADAG	Adagene Inc
10/11/2022	08:04	GlobeNewswire Inc.	Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors	NASDAQ:ADAG	Adagene Inc
11/10/2022	15:03	GlobeNewswire Inc.	Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November	NASDAQ:ADAG	Adagene Inc
10/09/2022	03:13	GlobeNewswire Inc.	Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors	NASDAQ:ADAG	Adagene Inc
30/08/2022	16:25	GlobeNewswire Inc.	Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates	NASDAQ:ADAG	Adagene Inc

Showing the most relevant articles for your search:NASDAQ:ADAG

Deutsche Telekom (QX)

Energy Select Sector SPDR

Verizon Communications

American Express

Euro vs US Dollar

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones